Skip to Content
Merck
CN
  • The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44.

The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44.

Biochemical and biophysical research communications (2022-08-17)
Géraldine David, David Reboutier, Stéphane Deschamps, Agnès Méreau, William Taylor, Sergi Padilla-Parra, Marc Tramier, Yann Audic, Luc Paillard
ABSTRACT

CD44 mRNA contains nine consecutive cassette exons, v2 to v10. Upon alternative splicing, several isoforms are produced with different impacts on tumor biology. Here, we demonstrate the involvement of the RNA-binding proteins CELF1 and ELAVL1 in the control of CD44 splicing. We show by FRET-FLIM that these proteins directly interact in the nucleus. By combining RNAi-mediated depletion and exon array hybridization in HeLa cells, we observe that the exons v7 to v10 of CD44 are highly sensitive to CELF1 and ELAVL1 depletion. We confirm by RT-PCR that CELF1 and ELAVL1 together stimulate the inclusion of these exons in CD44 mRNA. Finally, we show in eight different tumor types that high expression of CELF1 and/or ELAVL1 is correlated with the inclusion of CD44 variable exons. These data point to functional interactions between CELF1 and ELAVL1 in the control of CD44 splicing in human cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
Monoclonal Anti-Proliferating Cell Nuclear Antigen antibody produced in mouse, clone PC 10, ascites fluid